Year All20232022202120202019201820172016201520142013201220112009 Jul 26, 2023 REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights Jul 24, 2023 REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting Jul 11, 2023 REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023 Jun 27, 2023 REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates Jun 20, 2023 REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement Lawsuit Jun 01, 2023 REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference May 23, 2023 REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome
Jul 26, 2023 REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights
Jul 24, 2023 REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting
Jul 11, 2023 REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023
Jun 27, 2023 REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates
Jun 20, 2023 REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement Lawsuit
May 23, 2023 REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome
